Anna Fabisiewicz 1 , Andrzej Tysarowski 1 ,Michal Osowiecki 2 ,

1. Progression- free survival curve in whole group of patients 1,0 0,8 0,6 Probability of PFS 0,4 0,2 V 0,0 V/F 0 20 40 60 80 100 120 140 160 180 200 Months 0 10 20 30 40 50 60 70 Months Progression- free survival in whole group of patients Overall survival curve in whole group of patients 1,0 1,0 0,8 0,8 0,6 0,6 Probability of PFS Probability of OS 0,4 0,4 0,2 0,2 H/R H/R 0,0 0,0 R 0 20 40 60 80 100 120 140 160 180 200 R 0 50 100 150 200 250 300 H H Months Months Progression- free survival in DLBCL group Overall survival curve in DLBCL group 1,0 1,0 0,8 0,8 0,6 0,6 Probability of PFS Probability of OS 0,4 0,4 0,2 0,2 H/R H/R 0,0 0,0 R R 0 5 10 15 20 25 30 35 40 45 0 10 20 30 40 50 60 70 H H Months Months FcRgIIIa and FcRgIIa polymorphisms do not influence overall survival in follicular and diffuse large B-cell lymphoma patients treated with rituximab Anna Fabisiewicz1, Andrzej Tysarowski1,Michal Osowiecki2, Ewa Paszkiewicz-Kozik2, Jan Walewski2, Janusz A. Siedlecki1 MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER-INSTITUTE, Roentgena 5, 02-781 Warsaw, POLAND 1Department of Molecular Biology, 2Hemato - Oncology Intensive Care Unit, Lymphoma Department, e-mail: fabisiewicz@coi.waw.pl FcγRIIIa allele INTRODUCTION In follicular lymphoma (FL) genomic polymorphisms corresponding to the expression of valine (V) or phenyloalanine (F) in position 158 of FcgRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) and consequently response to rituximab. Patients with FcgRIIIa-158V genotype have longer progression free survival (PFS) than with 158F or 158 V/F genotypes. In contrast,in diffuse large B-cell lymphoma (DLBCL) this polymorphism not correlate with survival but is predictive of response to rituximab+ chemotherapy treatment (R+ CHOP). Previous studies have also shown that FcgRIIa -131 polymorphism is not associated with response to rituximab. The current study evaluated the impact of FcgRIIIa -158 andFcgRIIa -131 polymorphisms on long overall survival (OS) and progression free survival (PFS) in FL and DLBCL patients treated with rituximab. Overall survival curve in whole group of patients 1,0 0,8 0,6 Probability of OS 0,4 0,2 V 0,0 V/F 0 50 100 150 200 250 300 F F Months Progression- free survival curve in DLBCL group Overall survival curve in DLBCL group 1,0 1,0 0,8 0,8 0,6 0,6 Probability of OS 0,4 0,4 Pcia 0,2 0,2 V V 0,0 0,0 V/F V/F 0 5 10 15 20 25 30 35 40 45 F F Months MATERIALS AND METHODS Two single- nucleotide polymorphisms of FcgRIIIa and FcγRIIawere examined by PCR-RFPL method in a group of 124 patients treated with rituximab as previously described. 51 patients had FL, 73 patients had DLBCL. Median time of observation was 31 months (range 12-144 months). The median 6 cycle of R was given ( range 1-8), mainly as R-CHOP theraphy. FcγRIIa allele Patient’s characteristics and treatment outcomes Response to rituximab according to FcγRIIIa and FcγRIIaallele CONCLUSION Although the differences in OS and PFS after 70 months and later were observed for FcγRIIIa-158 and FcγRIIa-131 polymorphisms, those differences were not statistically significant. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease